Alogliptin protects Cardiovascular diesase by modurating micro-RNA for diabetis patients
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000009714
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Not provided
Patients meeting one of the following conditions will be excluded: 1.Under treatment with a thiazolinean, dual or more diabetis drugs, other DPP-4 inhibitors or insulin at the time of study initiation 2. Type 2 and secondary diabetes 3. Severe infectious disease, before or after surgery, and severe trauma 4. Events of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction 5. Moderate renal dysfunction (Serum creatinine (mg/dL): male, 1.4<; female, 1.2<) 6. Severe liver dysfunction (AST: 100 IU/l or higher) 7. Moderate or severer heart failure) (NYHA/New York Heart Association stage III or severer) 8. Under insulin treatment 9. Under treatment with therapeutic drugs not concomitantly administrable with incretin preparations, such as DPP-4 inhibitors, with regard to national health insurance, at the time of study initiation 10. Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 11. Past medical history of hypersensitivity to investigational drugs 12) Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The changes in the serum micro-RNA during a 6-month treatment period
- Secondary Outcome Measures
Name Time Method The changes of following data 1.FBS, HbA1c 2.urinary micro albmin 3.BUN, Cr, Cystatine C 4.the grade of diebetis retinopaty